Annual report
6545.TEDINET S100QW4N
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Key figures · 120
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥4.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥99m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥156m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥149m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥290m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥107m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥287m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥35m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥186m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥35m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥186m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥3.2bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.8bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥1.9bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.6bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥845m | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥303m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥272m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥302m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥236m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥24m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥250m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥6.5 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.67 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥6.36 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.74 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥238.79 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥231.64 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 40.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 374 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 329 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥3.5bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥165m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥148m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥7m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥281m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥250m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥216m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥104m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥49m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥278m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥31m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥187m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥150m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥65m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.3bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.5bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥853m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥816m | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥696m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥845m | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥930m | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥430m | at 2019-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥362m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥395m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥154m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥104m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥170m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥168m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥343m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥275m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥39m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.66 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.85 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.08 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.96 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.12 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥33.91 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.29 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.21 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥11.64 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥222.67 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥232.38 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥190.07 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥160.09 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥150.79 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 45.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.5% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,427,771 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,413,371 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 202 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 296 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 319 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 301 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 292 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 33
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥6m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥603m |
| Health Care Solution Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥113m |
| Health Care Solution Businessreportable segment | employees | at 2023-03-31 | 237 pure |
| Health Care Solution Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Health Care Solution Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Health Care Solution Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥418m |
| Home Care Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥8m |
| Home Care Businessreportable segment | employees | at 2023-03-31 | 108 pure |
| Home Care Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥285m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥121m |
| —segment total | employees | at 2023-03-31 | 345 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥703m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥4m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥560m |
| Health Care Solution Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥121m |
| Health Care Solution Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Health Care Solution Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Health Care Solution Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥338m |
| Home Care Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥7m |
| Home Care Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥378m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥128m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥716m |
| Health Care Solution Businessreportable segment | employees | at 2023-03-31 | 173 pure |
| —segment total | employees | at 2023-03-31 | 173 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,278
| Item | Context | Value | Unit |
|---|---|---|---|
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Policy on human resource development and improvement of internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Reference to other information risk management | FilingDateInstant | Original text (Japanese)「第２ 事業の状況 ３事業等のリスク」 | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on human resource development and improvement of internal environment and targets and results using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Reference to other information metrics and targets | FilingDateInstant | Original text (Japanese)「第１ 企業の概況 ５従業員の状況」 | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)完全議決権株式であり、権利内容に何ら限定のない当社の標準となる株式であります。なお、単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |